MAP’s research cited in APPG evidence sessions
MAP’s research has been cited by members of industry giving evidence to the APPG on Access to Medicines and Medical … read more »
MAP referenced at APPG for Life Sciences
MAP BioPharma’s report Access to Orphan Medicines: A Case for Change was reference at last week’s APPG for Life Sciences … read more »
MAP hosts Parliamentary event on access to rare disease medicines
Last week MAP BioPharma welcomed leading stakeholders to join representatives from companies from the Access to Orphan Medicines Steering Group* … read more »
Parliament debates NICE appraisals of rare disease treatments
Last Thursday MPs debated a motion that this House believes that NICE appraisal processes do not properly address the medical … read more »
Changes to the procedure for accessing the AIFA 5% fund
MAP’s partner in Italy, Regulatory Pharma Net, has communicated that the AIFA have made changes to the procedure for accessing the … read more »
New report from MAP BioPharma on access to orphan medicines
MAP BioPharma (MAP) has published a report on access to orphan medicines in England. The report, Access to Orphan Medicines: … read more »
